Levosimendan + Placebo

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Heart Failure

Conditions

Heart Failure

Trial Timeline

Aug 1, 2019 → Jul 30, 2020

NCT ID

NCT03576677

About Levosimendan + Placebo

Levosimendan + Placebo is a approved stage product being developed by Orion Corporation for Heart Failure. The current trial status is unknown. This product is registered under clinical trial identifier NCT03576677. Target conditions include Heart Failure.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure were approved

Approved (20) Terminated (2) Active (0)

✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅regadenosonAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03576677	Approved	UNKNOWN	Aug 1, 2019	Jul 30, 2020	Heart Failure
NCT02261948	Approved	Completed	Sep 1, 2012	Dec 1, 2014	Heart Failure
NCT01721434	Phase 2/3	UNKNOWN	Sep 1, 2012	May 1, 2016	Muscle Weakness Conditions
NCT01022983	Approved	Withdrawn	Apr 1, 2011	Dec 1, 2012	Heart Failure
NCT01065194	Phase 3	UNKNOWN	Aug 1, 2009	Aug 1, 2011	Chronic Stable Heart Failure
NCT00698763	Phase 2	Completed	Aug 1, 2008	Sep 1, 2009	Transient Ischemic Attack

Competing Products

20 competing products in Heart Failure

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	43
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35